Outlook Therapeutics CFO Lawrence Kenyon acquires 101,010 common shares valued at $99,999.9

Reuters2026/08/14 23:40

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Outlook Therapeutics CFO Lawrence A. Kenyon bought 101,010 common shares in an underwritten public offering priced at $0.99 per share.
Kenyon’s direct ownership rose to 106,956 shares following the purchase.
He also bought 101,010 warrants exercisable at $1.1, expiring Aug. 14, 2031.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001649989-26-000009), on August 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Outlook Therapeutics CFO Lawrence Kenyon acquires 101,010 common shares valued at $99,999.9

You may also like

Crypto prices